|
1
|
Yeshurun M, Labopin M, Blaise D, et al:
Impact of postremission consolidation chemotherapy on outcome after
reduced-intensity conditioning allogeneic stem cell transplantation
for patients with acute myeloid leukemia in first complete
remission: a report from the Acute Leukemia Working Party of the
European Group for Blood and Marrow Transplantation. Cancer.
120:885–863. 2014.
|
|
2
|
Dale DC, McCarter GC, Crawford J and Lyman
GH: Myelotoxicity and dose intensity of chemotherapy: reporting
practices from randomized clinical trials. J Natl Compr Canc Netw.
1:440–454. 2003.PubMed/NCBI
|
|
3
|
Zhong XY, Zhang B, Asadollahi R, et al:
Umbilical cord blood stem cells: what to expect. Ann NY Acad Sci.
1205:17–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wagner JE and Gluckman E: Umbilical cord
blood transplantation: the first 20 years. Semin Hematol. 47:3–12.
2010.PubMed/NCBI
|
|
5
|
Sun HP, Zhang X, Chen XH, et al: Human
umbilical cord blood-derived stromal cells are superior to human
umbilical cord blood-derived mesenchymal stem cells in inducing
myeloid lineage differentiation in vitro. Stem Cells Dev.
21:1429–1440. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang WZ, Zhang Y, Wu F, et al: Safety
evaluation of allogeneic umbilical cord blood mononuclear cell
therapy for degenerative conditions. J Transl Med. 8:752010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang XZ, Xu YL and Tian R: The research
and application of cord blood plasma. Lin Chuang Xue Ye Xue Za Zhi.
1:39–40. 2003.(In Chinese).
|
|
8
|
Liao C, Liu B and Huang Y: Establishment
of cord blood stem cell bank and its clinical application. Zhonghua
Xue Ye Xue Za Zhi. 22:411–414. 2001.(In Chinese).
|
|
9
|
Isasi R, Dalpe G and Knoppers BM:
Fostering public cord blood banking and research in Canada. Stem
Cells Dev. 22(Suppl 1): 29–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang BH, Zhang MZ, Fu XR, et al:
Pathogenesis, prevention and treatment of chemotherapy and
radiotherapy induced myelosuppression: the state of the art. Zhong
Liu Ji Chu Yu Lin Chuang Za Zhi. 26:162–165. 2013.(In Chinese).
|
|
11
|
Duong CD and Loh JY: Laboratory monitoring
in oncology. J Oncol Pharm Pract. 12:223–236. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lv M and Huang XJ: Allogeneic
hematopoietic stem cell transplantation in China: where we are and
where to go. J Hematol Oncol. 5:102012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Riordan NH, Chan K, Marleau AM and Ichim
TE: Cord blood in regenerative medicine: do we need immune
suppression. J Transl Med. 5:82007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang XF, Wang GZ, Li GX, et al:
Transplantation of unrelated donor umbilical cord blood in 28
patients with malignant hematopathy. Zhonghua Xue Ye Xue Za Zhi.
27:279–280. 2006.(In Chinese).
|
|
15
|
Gu DS, Liu B and Han ZC: The research and
application of cord blood stem cells. Zhongguo Ke Xue Yuan Sheng Wu
Ke Xue Yu Ji Shu Ju. 18:323–327. 2006.(In Chinese).
|
|
16
|
Wang XH, Zhang XZ, Shi HZ, et al: The
evaluation of Epo, G-CSF, IL-2, IL-6 in cord blood plasma. Zhonghua
Xue Ye Xue Za Zhi. 11:391999.(In Chinese).
|
|
17
|
Biesecker LG and Emerson SG: Interleukin-6
is a component of human umbilical cord serum and stimulates
hematopoiesis in embryonic stem cells in vitro. Exp Hematol.
21:774–778. 1993.PubMed/NCBI
|
|
18
|
Sanders M, Sorba S and Dainiak N:
Insulin-like growth factors stimulate erythropoiesis in
serum-substituted umbilical cord blood cultures. Exp Hematol.
21:25–30. 1993.PubMed/NCBI
|
|
19
|
Carow CE, Hangoc G and Broxmeyer HE: Human
multipotential progenitor cells (CFU-GEMM) have extensive replating
capacity for secondary CFU-GEMM: an effect enhanced by cord blood
plasma. Blood. 81:942–949. 1993.
|
|
20
|
An YH, Zhou RX, Zhang GJ, et al:
Transplantation of cord blood hematopoietic stem cells: effects on
marrow function of cancer patients on chemotherapy. Qingdao Da Xue
Yi Xue Yuan Xue Bao. 36:88–90. 2000.(In Chinese).
|
